MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of bax and maintenance of survivin

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4309-4319

  Nardiello, Tricia ^a   Jungbluth, Achim A ^b   Mei, Anna ^a   DiLiberto, Maurizio ^c   Huang, Xiangao ^c   Dabrowski, Ania ^a   Andrade, Valéria C C ^a   Wasserstrum, Rebecca ^a   Ely, Scott ^c   Niesvizky, Ruben ^c   Pearse, Roger ^c   Coleman, Morton ^c   Jayabalan, David S ^c   Bhardwaj, Nina ^a   Old, Lloyd J ^b   Chen Kiang, Selina ^c   Cho, Hearn Jay ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; KI 67 ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; SHORT HAIRPIN RNA; SURVIVIN;

ADULT; AGE DISTRIBUTION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 13; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; TRISOMY;

ANTIGENS, NEOPLASM; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960329490     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1820     Document Type: Article

References (22)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
2. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32. (Pubitemid 35398862)
3. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005;106:167-74. (Pubitemid 40967189)
4. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111:2962-72.
5. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A 2006;103:11160-5. (Pubitemid 44156489)
6. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 2007;67:9954-62. (Pubitemid 47621245)
7. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 2010;95:785-93.
8. Doyle JM, Gao J, Wang J, Yang M, Potts PR. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Molecular cell 2010;39:963-74.
9. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
10. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60. (Pubitemid 32467376)
11. Ely SA, Chadburn A, Dayton CM, Cesarman E, Knowles DM. Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer 2000;89:445-52. (Pubitemid 30489896)
12. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004;79:867-74. (Pubitemid 38879952)
13. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51. (Pubitemid 32694940)
14. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9. (Pubitemid 24299325)
15. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4. (Pubitemid 28563719)
16. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008;14:5000-5.
17. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002;277:3247-57. (Pubitemid 34953189)
18. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002;21:2613-22. (Pubitemid 34478319)
19. Romagnoli M, Séveno C, Wuilléme-Toumi S, Amiot M, Bataille R, Minvielle S, et al. The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. Br J Haematol 2009;145:180-9.
20. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007;67:2982-9. (Pubitemid 46724834)
21. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007;109:1103-12. (Pubitemid 46220657)
22. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 2007;25 Suppl 2:B61-71.